Taysha Gene Therapies Inc (TSHA)
Healthcare
Biotechnology
—
5.90 $
-0.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Taysha Gene Therapies Inc (TSHA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.7% of the shares are freely tradable; institutional investors hold 95.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
95.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
10.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
71.7%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
13.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
287Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RA Capital Management, LLC | 8.20 | 23,555,648 | +0.0 | 03/31/2026 |
| The Goldman Sachs Group Inc | 7.78 | 22,369,645 | +63.4 | 03/31/2026 |
| venBio Select Advisor LLC | 7.55 | 21,700,000 | +0.0 | 03/31/2026 |
| BlackRock Inc | 6.39 | 18,365,608 | -1.5 | 03/31/2026 |
| Vestal Point Capital LP | 6.26 | 18,000,000 | +30.9 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 6.25 | 17,965,371 | -0.6 | 03/31/2026 |
| FMR Inc | 4.98 | 14,321,255 | +5.9 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 4.76 | 13,680,248 | -16.6 | 03/31/2026 |
| Vanguard Group Inc | 4.62 | 13,267,805 | +3.3 | 12/31/2025 |
| State Street Corp | 3.90 | 11,209,078 | +3.9 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.